Literature DB >> 17983750

Where and how do anthrax toxins exit endosomes to intoxicate host cells?

Andrea Puhar1, Cesare Montecucco.   

Abstract

The role of Bacillus anthracis virulence factors in its pathogenesis has been subjected to intense investigation with the aim of finding novel preventive and therapeutic protocols. Toxins that are endocytosed and act in the cytosol of host cells have a central role in B. anthracis infection. Understanding of anthrax toxin cell entry has increased during the past few years and a composite picture is emerging. Nevertheless, unanswered and controversial questions remain, particularly concerning the site and mode of anthrax toxin cell entry, the role of anthrax toxin receptors in the process and the possible involvement of cytosolic chaperones, which might affect entry efficiency. Here, the current model of anthrax toxin cell entry, an alternative model and experimental approaches for clarifying unanswered questions will be discussed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17983750     DOI: 10.1016/j.tim.2007.10.003

Source DB:  PubMed          Journal:  Trends Microbiol        ISSN: 0966-842X            Impact factor:   17.079


  11 in total

Review 1.  A novel pathway for exotoxin delivery by an intracellular pathogen.

Authors:  Stefania Spanò; Jorge E Galán
Journal:  Curr Opin Microbiol       Date:  2008-02-20       Impact factor: 7.934

2.  Thioamide hydroxypyrothiones supersede amide hydroxypyrothiones in potency against anthrax lethal factor.

Authors:  Arpita Agrawal; César Augusto F de Oliveira; Yuhui Cheng; Jennifer A Jacobsen; J Andrew McCammon; Seth M Cohen
Journal:  J Med Chem       Date:  2009-02-26       Impact factor: 7.446

3.  Effect of late endosomal DOBMP lipid and traditional model lipids of electrophysiology on the anthrax toxin channel activity.

Authors:  Nnanya Kalu; Yoav Atsmon-Raz; Sanaz Momben Abolfath; Laura Lucas; Clare Kenney; Stephen H Leppla; D Peter Tieleman; Ekaterina M Nestorovich
Journal:  Biochim Biophys Acta Biomembr       Date:  2018-08-23       Impact factor: 3.747

Review 4.  Membrane translocation by anthrax toxin.

Authors:  R John Collier
Journal:  Mol Aspects Med       Date:  2009-06-27

5.  Blockage of anthrax PA63 pore by a multicharged high-affinity toxin inhibitor.

Authors:  Ekaterina M Nestorovich; Vladimir A Karginov; Alexander M Berezhkovskii; Sergey M Bezrukov
Journal:  Biophys J       Date:  2010-07-07       Impact factor: 4.033

6.  Anthrax toxin triggers the activation of src-like kinases to mediate its own uptake.

Authors:  Laurence Abrami; Béatrice Kunz; F Gisou van der Goot
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

7.  Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma.

Authors:  Randall W Alfano; Stephen H Leppla; Shihui Liu; Thomas H Bugge; Janelle M Ortiz; Terry C Lairmore; Nicholas S Duesbery; Ian C Mitchell; Fiemu Nwariaku; Arthur E Frankel
Journal:  Mol Cancer Ther       Date:  2010-01-06       Impact factor: 6.261

8.  Matrix metalloproteinase-activated anthrax lethal toxin inhibits endothelial invasion and neovasculature formation during in vitro morphogenesis.

Authors:  Randall W Alfano; Stephen H Leppla; Shihui Liu; Thomas H Bugge; Cynthia J Meininger; Terry C Lairmore; Arlynn F Mulne; Samuel H Davis; Nicholas S Duesbery; Arthur E Frankel
Journal:  Mol Cancer Res       Date:  2009-04       Impact factor: 5.852

9.  Cytotoxicity of the matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells.

Authors:  Randall W Alfano; Stephen H Leppla; Shihui Liu; Thomas H Bugge; Meenhard Herlyn; Keiran S Smalley; Jennifer L Bromberg-White; Nicholas S Duesbery; Arthur E Frankel
Journal:  Mol Cancer Ther       Date:  2008-05       Impact factor: 6.261

10.  Anthrax edema toxin modulates PKA- and CREB-dependent signaling in two phases.

Authors:  Andrea Puhar; Federica Dal Molin; Stéphanie Horvath; Daniel Ladant; Daniel Ladants; Cesare Montecucco
Journal:  PLoS One       Date:  2008-10-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.